The Liver Meeting: Vir Biotechnology presented data from programs for chronic hepatitis B and chronic hepatitis delta
Vir Chief Medical Officer Mark Eisner discusses the MARCH Phase 2 study results for hepaitis B, and Hôpital Beaujon Professor of Hepatology Tarik Asselah discusses the SOLSTICE Phase 2 study results for hepatitis delta.